| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | MI-1 | CTRPv2 | pan-cancer | AAC | -0.095 | 0.02 |
| mRNA | BRD-K96431673 | CTRPv2 | pan-cancer | AAC | -0.17 | 0.02 |
| mRNA | MGCD-265 | CTRPv2 | pan-cancer | AAC | 0.081 | 0.02 |
| mRNA | ML162 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.02 |
| mRNA | quizartinib | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | ML210 | CTRPv2 | pan-cancer | AAC | -0.076 | 0.02 |
| mRNA | tanespimycin:bortezomib (250:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.085 | 0.02 |
| mRNA | ruxolitinib | CTRPv2 | pan-cancer | AAC | 0.078 | 0.02 |
| mRNA | BRD-K64610608 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.02 |
| mRNA | AZD7762 | CTRPv2 | pan-cancer | AAC | 0.072 | 0.03 |